• The podcast is hosted by Executive Coach and Speaker Sergio Tigera, who spent half an hour discussing Anstey’s cryptocurrency past, present, and future
• The LQwD CEO shared his unique perspective on the journey, mindset, struggles, and successes accomplished
• The PaaS offered by LQwD was released November 17 and makes Bitcoin’s Lightning Network easy to use and allowing for low fees, faster transactions and the ability to make micro-transactions

The December 21 episode of Gamechangers LIVE(R) featured the Co-Founder, Chairman, and CEO of LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), Shone Anstey. LQwD is a fintech company that focuses on creating enterprise-grade infrastructure to drive Bitcoin adoption. The Gamechangers LIVE podcast is a series that puts a spotlight on individuals who are game-changers in their respective fields or industry. During the podcast, Anstey was able to share a unique perspective on the journey, mindset, struggles, and successes accomplished – all to inspire and inform Gamechangers LIVE(R) listeners (https://ibn.fm/fJvRM). Executive Coach and Speaker Sergio Tigera hosted the Gamechangers LIVE(R) podcast. During the interview, Anstey talked about his background in the cryptocurrency industry, including his co-founding of BIGG Digital Assets (CSE: BIGG) (OTCQX: BBKCF), and then turned his attention to the Lightning Network. “I started BIGG Digital Assets late in 2014. We went through crypto winter, survived all of that, came out the other side, and built a great compliance software. In 2019, we bought Netcoins and bolted on our compliance software to create a compliance-first exchange,” Anstey said, underlining that BIGG has now become one of Canada’s largest exchanges. “I’m still with BIGG as a director and large shareholder, but my full-time focus has been on LQwD for the past two years.” After discussing his BIGG venture, Anstey discussed the Lightning Network and LQwD’s overlay for the network, which is designed to improve the overall transactional process. “When Bitcoin came around, it just was like ‘hey, this is just an extension of the internet.’ Everything that we’re doing here is just a continuation of the revolution of the internet. I came from an analytics background. I’m a pragmatic person. I was looking at how to take Bitcoin mainstream and how to take crypto mainstream,” Anstey explained his approach and motivation during the interview. The LQwD CEO offered some of his own insight into Bitcoin’s Lightning Network, the benefits it provides, and its future. “The Lightning Network solves Bitcoin’s scalability issue. At seven transactions per second, Bitcoin is very slow and very secure. If you want to transfer $100 million worth of Bitcoin, the main network is absolutely acceptable, but if you want to use Bitcoin every day for coffee or purchases or remittances of smaller denominations, the Lightning Network allows you to send really small amounts more quickly. It offers a real solution to the scaling problem,” he said. Anstey added that the Lightning Network has been experiencing rapid growth over the last five years, with a 205% increase of the network in terms of nodes, channels, and capital this year alone. The largest point that Anstey made during the interview with Tigera focused on the benefits and scalability of Bitcoin’s Lightning Network. LQwD has leveraged these features, using the advantages of the Lightning Network and the necessity of a scalable solution for remitting smaller payments more quickly, which is where the company’s platform-as-a-service (PaaS), lqwd.tech, factors in. LQwD’s PaaS was released earlier last month, November 17, offering an alternative to the traditional blockchain transactions – the Lightning Network offers fewer fees, quicker transaction settlements, and transaction security. LQwD’s PaaS aims to empower institutions, businesses, and investors making the Lightning Network easy to work with, lqwd.tech was designed to be scalable and adaptive to the fast-paced growth of the Network, allowing for millions of Bitcoin transactions in seconds. LQwD expects that the Lightning Network will be a force for change globally and become the global monetary exchange of the future. For more information, visit the company’s website at www.LQwDFinTech.com. NOTE TO INVESTORS: The latest news and updates relating to LQWDF are available in the company’s newsroom at https://ibn.fm/LQWDF

• The point-of-care testing market is projected to be valued at $81.37 billion by 2028, representing a CAGR of 9.4% over the forecast period (2020-2028)
• Avricore plans to capitalize on this growth through investing in its technology and forging strategic partnerships that bring its services closer to patients
• For the 2021 calendar year, Avricore partnered with Shoppers Drug Mart pharmacy to pilot its HealthTab(TM) platform in specific locations
• Having capitalized and executed several critical agreements for 2021, the company is confident that it is well-positioned for growth in 2022

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF), a pharmacy service innovator, has remained focused on acquiring and developing early-stage tech, intending to move pharmacy forward. Its flagship offering, HealthTab(TM), seeks to offer turnkey point-of-care testing solutions, so far covering key ailments such as diabetes, cardiovascular conditions, and Covid-19. Avricore’s goal is to reach as many people as possible, and one way it is planning to achieve this is by partnering with community pharmacies. By equipping these drugstores with their state-of-the-art Afnion 2(TM) analyzers provided by Abbott Rapid Diagnostics, patients can get results in less than 10 minutes. This allows them to spend more time improving their health and less time waiting around for test results, as was previously the case. So far, in the 2021 calendar year, Avricore has partnered with Shoppers Drug Mart pharmacies to pilot the HealthTab platform in specific locations (https://ibn.fm/NMZ6v). The success of their partnership has shown the platform’s potential and the value that it brings, not just to patients but also to the company. As Avricore works towards being the world’s largest health diagnostics solutions provider, strategic partnerships with community pharmacies have proven to be integral to achieving this goal. It is projected that by 2028, the global point-of-care testing (“POCT”) market will be valued at $81.37 billion, up from $34.49 billion in 2020. This will represent a compound annual growth rate (“CAGR”) of 9.4%, primarily driven by the increased demand for screening and management tools for chronic diseases, coupled with the rapid assessment of infectious diseases such as Covid-19 (https://ibn.fm/kjJ8G). Avricore recognizes this opportunity, hence its investment in its technology and forging strategic partnerships that bring it even closer to patients, including those in rural areas. Going into 2022, the company is confident that it will realize strong growth given its milestones over the 2021 calendar year. “We’ve had our best year yet, despite many external factors that created headwinds, and we’re extremely excited to head into 2022,” noted Hector Bremner, the Chief Executive Officer (“CEO”) of Avricore. “Given that we are well capitalized and have executed several key agreements already, we’re well positioned for growth,” he added (https://ibn.fm/3mYf7). Avricore promises to help patients and create value for its shareholders, one community pharmacy at a time, a critical factor that will contribute to its growth for the 2022 calendar year. For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• USPTO notice marks important milestone in the expansion of CYBN’s intellectual property portfolio
• Once issued, patent may have opportunity to cover a broad range of claims
• Anxiety disorders are one of the most common mental illnesses in the United States

Cybin (NEO: CYBN) (NYSE American: CYBN) has taken another step forward in its commitment to progressing Psychedelics to Therapeutics(TM). The biopharmaceutical company has received a notice of allowance from the U.S. Patent and Trademark Office (“USPTO”) in regard to its patent application connected to its investigational deuterated psychedelic tryptamine compound for the potential treatment of anxiety disorders (https://ibn.fm/fpjXm). “The receipt of this notice of allowance from the USPTO represents an important milestone in expanding our intellectual property portfolio progressing psychedelics to therapeutics for the countless patients in need, and strongly demonstrates the company’s dedication to the discovery and development of differentiated psychedelic-based compounds for addressing mental health,” said Cybin CEO Doug Drysdale. “Once issued, this patent may have the opportunity to cover a broad range of claims supporting our IP in psychedelic medicine and further strengthen our emerging best-in-class position in this evolving industry.” Cybin applied for the patent to study CYB004, its proprietary psychedelic tryptamine compound with the potential to effectively treat anxiety disorders without the common side effects associated with current treatments. The potential for this sector is significant, as anxiety disorders are one of the most common mental illnesses in the United States. Based on reports from the U.S. National Institute of Mental Health, an estimated 40 million adults, or approximately 18% of the population, deal with anxiety disorders. And while many treatments are available, the success of these treatments is underwhelming, with up to 50% of patients with general anxiety disorder failing to respond to first-line treatments. In addition, “current standardized treatments for anxiety disorders also require chronic administration of medicines that have a long time to onset and present several potential side effects including weight gain, gastrointestinal disturbances, sexual dysfunction and withdrawal symptoms,” the company reports. Cybin hopes to solve many of these issues with its CYB004 compound, as well as other compounds it is developing. The USPTO note of allowance includes other forms of deuterated psychedelic tryptamine, the announcement reported, including certain deuterated forms of CYBN’s DMT and 5-MeO-DMT formulations. A leading ethical biopharmaceutical company, Cybin is working with a network of world-class partners and internationally recognized scientists to create safe and effective therapeutics for patients to address a multitude of mental health issues. The company operates in the United States, the United Kingdom and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Global supply chain disruptions are set to spread to the North American cannabis market
• Supply shortages are already being felt in the manufacture of vaping devices and specialty packaging with rising concerns that these could extend to raw cannabis flower supply
• American Cannabis Partners has distinguished itself through both a strict focus on a vertically integrated business model as well as through its adherence to unique Jamaican cultivation techniques
• The company now has plans to expand operations to a third state in 2022 and a fourth state by 2024

A shortage of Nutella and new automobiles, higher gas prices, and delayed deliveries on Christmas presents can all be linked to ongoing and major disruptions in the global supply chain. However, and in a largely unforeseen twist, shortages have now extended to the North American cannabis market. Rolling power outages in China, incessant shipping disruptions and the upcoming Chinese Lunar New Year holiday are increasingly set to play havoc on the global cannabis supply chain. The shortages and resulting impact on cannabis supply has led to a greater premium being placed on vertically integrated producers, with American Cannabis Partners (“ACP”) — a multi-state 100% organic cannabis cultivation company headquartered within Northern California’s Emerald Triangle — a key proponent of the business model. A recent survey delving into vaporizer use among cannabis consumers in the United States found that 37% of respondents had reported vaping cannabis in the past 30 days, with respondents revealing that they found the experience to be healthier, better tasting, producing better effects, and generally more satisfying in nature (https://ibn.fm/eKiCN). However and in a recent interview with New York-based vaping device manufacturer, Blinc Group, the company’s Chief Executive stated that they were finding increasing supply shortages in six of the 13 components which went into vape hardware, with disruptions and delays set to intensify ahead of the onset of the Lunar New Year holiday (https://ibn.fm/ODmL2). “I believe this issue will go on at least until the end of May [2022],” stated Blinc Group CEO Dumas de Rauly. “[However] it is not just vape devices. The raw material for the equipment that fills them with cannabis, the LEDs for the grow houses — all of it comes from China.” The cannabis industry has been shielded from supply-chain woes thus far, largely due to its hyper-local nature. As it is still classed as a Schedule I substance, companies risk legal imbroglios unless they grow and process the plant in the state where it will be sold. While most companies have thus far only suffered from shipping delays on items such as vape cartridges and specialty packaging, they believe it is only a matter of time until shortages start to affect the raw cannabis product itself. “We’re trying to order ahead — we’re not paying more [yet], but we’re paying up front; also, we’ve begun to source domestic pools of inventory,” said Josh Krane, vice president of operations for 4Front Ventures, a US-based cannabis multi-state operator. Since its founding in 2018, American Cannabis Partners has sought to establish a foothold in two key U.S. cannabis markets — California and Michigan, through a sustainable, vertically-integrated model. Since inception, the company has acquired 12 cannabis licenses, including 20,000 sq. ft. of cultivation licenses in California and 540,000 sq. ft. of cultivation licenses and one retail license in Michigan. The company currently supplies approximately 80% of its whole flower product to third-party manufacturers and distributors; the remaining 20% is used in the manufacture and sale of its exclusive in-house brand, ZÜK. In addition to its self-sustaining model, American Cannabis Partners has sought to differentiate its product within an increasingly commoditized cannabis market through the company’s unique adherence to Jamaican cultivation practices, which has led the company to produce some of the most sought-after flowers in the United States. In fact, and following its most recent harvest, ACP revealed that it has already seen its new, patent pending strains marketed under their ZÜK brand, presold for 2021 (https://ibn.fm/QWO7L). (https://ibn.fm/K4ez5). As a result of its strict focus on acquiring its own real estate and their vertically integrated model, American Cannabis Partners now finds itself in an enviable position to expand into its third U.S. state in 2022 and its fourth in 2024 (https://ibn.fm/GZZoC). (https://ibn.fm/FhwhC). With the U.S. cannabis market set to touch a forecasted annual value of $115 billion by 2030 according to investment bank Piper Sandler (https://ibn.fm/Ygilv), ACP finds itself in an enviable position to grow and develop their business at a time when the rest of the industry finds itself subject to the vagaries of the global supply chain. For more information, visit the company’s website at www.ACPFarms.com. NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://ibn.fm/ACP

• Eat Well Investment Group has appointed Marc Aneed, the current President and Director, as its new CEO
• Mr. Aneed has over 20 years’ experience in the consumer-packaged goods (“CPG”) space, having worked on and launched multiple successful consumer products at The Quaker Oats Company and Glanbia PLC
• Eat Well, a company that combines the best of agribusiness, food tech, and consumer goods, is building a platform that covers all the segments of the supply chain
• The company expects to leverage the guidance from its management and advisory team to grow through acquisitions, the launch of new products, expanded contracts, and more

Fully-integrated seed-to-market company Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) recently appointed the current President and Director, Marc Aneed, as its new Chief Executive Officer (“CEO”), taking over from David Doherty who has retired (https://ibn.fm/fXEuU). An award-winning natural/wellness consumer products expert with 20 years’ experience, Mr. Aneed has previously worked at The Quaker Oats Company, a PepsiCo (NASDAQ: PEP) company, and Glanbia PLC, a global nutrition company. At The Quaker Oats Company, where he started his career, Mr. Aneed worked on iconic brands such as Gatorade and more. At Glanbia PLC, where he worked before joining Eat Well, Mr. Aneed led Amazing Grass, a leading plant nutrition and supplement company boasting over $100 million in retail sales, as well as Optimum Nutrition and Isopure, Glanbia’s Sports Nutrition brands in North America. In addition, he launched multiple successful consumer products resulting in collective retail sales of over $1 billion. He has also worked on numerous M&A transactions with a total value of more than $400 million. Mr. Aneed’s appointment dovetails with the company’s strategy of leveraging the expertise and experience of the management and leadership team to achieve success within the burgeoning plant-based foods market. During an October 2021 interview with TraderTV Live (https://ibn.fm/AGp0C), Mr. Aneed noted that the leadership team, which has cumulative experience spanning over 100 years, has been instrumental in the company’s journey toward quick profitability despite being a relatively new company – Eat Well is projecting CA$60 million in final revenue for 2021. Moving forward, the company expects to continue capitalizing on the guidance provided by its advisory and management team to grow through the launch of new products, acquisitions, expanded contracts with big CPG brands that will extend its global reach, and more. “We know as a management team how to prioritize the right sorts of investments. We look at top-line revenue that’s real, that’s got use cases and velocity, and is underpinned by great gross margins. We’re not new to this space… We have a lot of the right people in our team, and… we’re bringing a lot of global leaders into this ecosystem of ours,” commented Marc. Operating in the agribusiness, food tech, and consumer goods segments, Eat Well is building a platform covering the downstream, midstream, and upstream stages of the supply chain. This holistic approach, Mr. Aneed says, matters “because supply security integrated with food tech all the way down through to retail is one of the very rare but most critical things to do in this space, and that’s what we are doing by design at Eat Well Group.” For more information, visit the company’s website at www.EatWellGroup.com. NOTE TO INVESTORS: The latest news and updates relating to EWGFF are available in the company’s newsroom at https://ibn.fm/EWGFF

• Delic Corp is a leading psychedelic wellness platform with a business network which includes psychedelic wellness clinics, psilocybin research facilities, a famed psychedelic wellness event, and dedicated media and e-commerce platforms
• Delic’s CEO, Matt Stang recently joined the Gamechangers LIVE podcast to share his perspective on the development of the psychedelic industry along with Delic’s commercial evolution

Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leading psychedelic wellness platform committed to bringing science-backed benefits to its many stakeholders, has long been known for its role as a trailblazer of new medicines and treatments in the current environment. Its goal is to improve access to health benefits and reframe the conversation on psychedelics. The company has sought to achieve its goals through its string of related businesses, which include Ketamine Wellness Centers, the largest chain of psychedelic wellness clinics in the country; Delic Labs, the sole entity currently licensed by Health Canada to focus exclusively on research and development of psilocybin vaporization technology; Meet Delic, the company’s eponymous psychedelic wellness event; as well as media and e-commerce platforms, Reality Sandwich, and Delic Radio. Matt Stang, Co-founder and CEO of Delic Corp recently joined the Gamechangers LIVE podcast to share his perspective on the psychedelic industry and share insights into the evolution of Delic Corp into its current form (https://ibn.fm/ab0yt). During the interview, Stang elaborated on his colorful background within the alternative drugs sector, a journey which began when he interned at High Times, a leading counterculture publication which would go on to become the voice for the cannabis industry. “I started off as an intern. It’s one of those wonderful stories. I graduated from college and wrote a senior thesis on legalization of marijuana. My thesis was that, with the terrorist attacks of 9/11, we could bring conservatives on board to legalization with a ‘tax and regulate’ strategy,” Stang said. “I submitted it to a friend who was friends with the General Counsel. He read it, loved it, and asked me to come in and intern. So, a week after I graduated, I got an internship at High Times and worked my way up…” Stang would ultimately go on to become the owner and operator of High Times, a position which he leveraged in his attempt to play a role in legalizing cannabis usage across several different states. “Now, two-thirds or more of the country live under some form of cannabis legalization… The world is changing in front of our eyes. I think the same thing is happening with psychedelics, but on a greater level and federally legal, because you have the FDA reviewing favorable clinical data for multiple psychedelics right now,” he continued. The movement to decriminalize psilocybin, the key active ingredient within psychedelic drugs, kicked off in earnest a few years ago, with Denver, Colorado becoming the first city to decriminalize psilocybin in May 2019. The cities of Oakland and Santa Cruz, California, followed suit and decriminalized psilocybin in June 2019 and January 2020, respectively (https://ibn.fm/lucZB). However, the movement has gained further momentum in recent times, with the likes of actor Will Smith commenting on his use of ayahuasca (https://ibn.fm/6vlWC), and musician Lil Nas X saying he couldn’t have written the number one album of the year without gaining inspiration from a full-day mushroom trip alongside his producers (https://ibn.fm/5N3Zs). During the podcast, Stang also went on to elaborate on the beneficial nature of psychedelic drugs and its ability to effectively supplant traditional benzodiazepines. “You’ve got tons of people stuck on Xanax or Percocet or all of these ‘maintenance’ drugs that don’t actually change you at all. You take them every day and, for the four to six hours that they’re active, you feel better. When they wear off, you feel worse,” Stang added. “With our internal data, the ketamine that we utilize is having somewhere between a 70-80% efficacy rate, meaning people are curative or better from using it for a certain period of time. With MDMA, they had a 77% rate. With psilocybin, it was closer to 80%. The full podcast interview with Delic Corp Co-Founder and CEO, Matt Stang can be found here: https://youtu.be/QIF12RiuAOQ For more information, visit the company’s website at www.DelicCorp.com and the Meet Delic conference website at www.MeetDelic.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

• Flora Growth Corp. is a Canadian cannabis and wellness brand distributor operating from a cultivation base in central Colombia
• The company’s focus on sustainability guides its efforts to market products that are beneficial to their local communities as well as the world at large
• Market analysts predict 2022 will see the global CBD skin care market segment alone grow with a CAGR of 24.8 percent
• The COVID-19 pandemic is continuing to drive expansion of online retail that affects the cosmetics sector as well as clothing, groceries and other avenues that may include the more-than-190 cannabis-derivative products produced by Flora Growth

Plant-based wellness and lifestyle collective Flora Growth (NASDAQ: FLGC) is entering 2022 with momentum from the past year’s aggressive growth campaign for its global cannabis-derivative brand distribution of pharmaceuticals, cosmetics and nutraceuticals. While industry news has largely focused on M&A activity and questions about when the United States may grant federal legalization of cannabidiol (“CBD”) following the advance and then defeat of supportive banking measures in 2021, Canada-based Flora has been completing agreements with partners in numerous countries to expand its verticals from their cultivation origins in central Colombia. The COVID-19 pandemic has had a deleterious effect on the global sustainability agenda. An oil price crash made petroleum sources more attractive than alt fuels, the supply and demand of commodities faced challenges that drove price volatility, and seasonal reduction of infection levels has produced a renewed spike in environmental pollution (https://ibn.fm/vTBcC). Flora Growth has prioritized value-chain sustainability among each of its brands, acting at a local level to establish products that will have a beneficial effect on communities and the world at large under its guiding principles. Flora’s core product, organic cannabis oil, comes from an inherently natural and sustainable process at the company’s cultivation site in central Colombia, where all-outdoor production is fueled by 12.5 hours of natural sunlight per day and natural water springs. A pesticide-free agronomic management system tailored to the area’s climate and condition further ensures a natural quality to the products. The Cosechemos Cultivation Facility includes a research and development lab set on a 100-hectare (247-acre) property. The company recently began filling the initial orders for its Mind Naturals and Awe CBD skincare brands in Spain and Mexico (https://ibn.fm/XUC6A). They expect to begin a distribution of medical cannabis products throughout Europe during the coming year thanks to a pathway established through an investment program with European Union GMP partner Hoshi International Inc. (https://ibn.fm/6dFJv). European and Latin American markets for cannabis-derivative products are growing, and analysts at Allied Market Research issued a forecast shortly before Christmas that envisages the global CBD skin care market segment alone to grow from $633.6 million in 2018 to $3.48 billion by 2026 with a CAGR of 24.8 percent (https://ibn.fm/MMHht). “After months of preparation, our products meet all the needs of today’s consumers, and we are ready for new international markets. … Incorporating cutting edge formulations, rigorous safety standards and sustainable packaging, we are confident that our products are positioned to be among the best in the beauty industry,” Flora Beauty General Manager Andrew Restrepo stated when the Mind Naturals and Awe CBD orders were announced. The advance of Flora’s cosmetic brands builds on e-commerce agreements with SHOWFIELDS and GlossWire’s digital beauty marketplace, which were established in October. The Allied Market Research report anticipates growth in the e-commerce segment with a CAGR of 27.4 percent by 2026 as consumers increasingly turn to online access and distribution portals to receive products at their doorsteps. Forbes predicts that 2022 will “bring a digital revolution to retail” as department stores, chain stores and even grocery retailers see spiking sales figures in their internet sales, and CBD-based cosmetics are expected to ride that trend (https://ibn.fm/fK268). For more information, visit the company’s website at www.FloraGrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• FingerMotion received approval for its application for NASDAQ up-listing, and commenced trading on Tuesday, December 28, 2021, under the company’s current trading symbol, “FNGR”
• The approval marks a key milestone for the company as it plans to execute an ambitious growth strategy for the 2022 calendar year
• It marks FingerMotion’s second successful up-listing application with the first one (for the OTCQB Venture Marketplace) having gone through back in February 2019

FingerMotion (NASDAQ: FNGR) just announced listing its shares of common stocks on The Nasdaq Stock Market LLC (“Nasdaq”). The approval, which came on December 27, 2021, has seen FingerMotion become the latest technology company listed on the Nasdaq Capital Market, a move that offers the company great exposure within the investment community (https://ibn.fm/J8qfA). FingerMotion’s listing marks a significant milestone, particularly as it seeks to execute its ambitious growth strategy for the 2022 calendar year. While making the announcement, Martin Shen, the Chief Executive Officer (“CEO”) of FingerMotion, noted, “FingerMotion is very proud and excited to be joining the Nasdaq stock market as one of the newly listed technology companies.” “We believe that listing on a senior stock exchange will create more value for our shareholders, allow us to expand our investor base, and provide the opportunity to gain greater visibility for our fast-growing Company within the U.S. financial community,” he added. FingerMotion received its first upgrade back in February 2019 when it applied and got approval to trade on the OTCQB Venture Marketplace (https://ibn.fm/dLQLW). Then, in August 2021, the company submitted its application to be further up-listed on the Nasdaq Capital Market. Nasdaq trading commenced on December 28, 2021, under the current trading symbol, “FNGR.” For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• In an interview with Authority Magazine’s Charlie Katz, Rositano Jr. discussed the early years of the Fan Pass Live artist platform and how he and his brother (and business partner) found their niche with music and entertainment
• The interview includes an in-depth look at Rositano Jr.’s approach and unique business model, as well as what his role as CEO of Friendable and Fan Pass implies
• Rositano Jr. also offered valuable tips and advice for budding entrepreneurs, including the things he wished he knew before he ever became a founder

In a recent interview conducted by Charlie Katz for Authority Magazine, Robert A. Rositano Jr., co-founder, and CEO of mobile technology and marketing company Friendable (OTC: FDBL), added his story to the ongoing “5 Things I Wish Someone Told Me Before I Became A Founder” series (https://ibn.fm/86lxN). Authority Magazine offers in-depth interviews with those who hold “authority” in industries such as business, pop culture, wellness, tech, and more. Katz is the Executive Creative Director at Bitbean Software Development. In his role as the CEO, Rositano Jr. described what it is like to be an executive for the Fan Pass Live streaming platform and how it differs from other executives within the company’s infrastructure. During the interview, he summed up his role as one that requires him to “wear many hats, always staying in front of the operations and actionable items that need to happen daily, yet being hands-on enough to ensure they are being executed.” Rositano Jr. broke down his role into seven different bullet points:

• Providing customers, investors, and shareholders the painted picture and projection of the company’s vision
• Always seeking out new partners and opportunities
• Screening new ideas and concepts within team members that help to spark testing and creativity for the platform
• Being in charge of fundraising and capital raising efforts
• Driving new initiatives for revenue generation
• Reviewing, monitoring, and adjusting the company’s budget and spending continually
• Keeping track and monitoring the results

After the two discussed his role as CEO within the company, the true nature of the interview is addressed – the “5 Things I Wish Someone Told Me Before I Started.” Here is a highlight of what Rositano Jr. said in response to the question:

1. Projections are only projections – don’t begin your business on an idea (or conjectures)
2. The industry is not going to go as fast as you want it to – it’s a process
3. Always add a week of lead time to everything – even if your attorney tells you “tomorrow”
4. Keep testing (start with small audiences) and keep improving until it works
5. Don’t try to accomplish everything before you launch – you will never get off the ground

Rositano Jr. began the interview by discussing his backstory, underlining how his love of music was only the start of his passion for the music industry. It all began when he was a teenager, and his brother (and business partner) Dean Rositano formed a band in middle school. Rositano Jr. was involved in small productions, performances, and even accompanied the band to venues along the Sunset Strip in Hollywood – all before any of the members reached their 18th birthday. It was this experience that deeply instilled a love for the industry and reaffirmed that he and his brother would always have music or entertainment in their career, “no matter what.” The Fan Pass CEO also talked about how this passion for music and the industry as a whole which led to the creation of the Fan Pass platform and its focus on increasing artists’ revenue-generating opportunities while giving fans better and more affordable access to the artists they love. “We understood the amount of lost revenue each artist has, simply based on a limited number of fans who can afford or be in a particular city to attend a backstage meet & greet,” he explained. So the Rositanos approached these artists with the Fan Pass Live invention as some sort of “fly on the wall” for backstage experiences and livestream content that fans could view right from the palm of their hands/mobile device. “The concept was sound, the artists loved it and it was envisioned as a $2.99 monthly subscription (about the cost of a few songs from your favorite artist) this would create an entirely new revenue stream, as Fan Pass would be sharing a portion of the $2.99 with each artist on a recurring monthly basis,” Rositano Jr. said. Toward the conclusion of the interview, Rositano Jr. was asked about his favorite life lesson quote – “If you don’t quit… you can’t fail.” This quote has held true in many aspects of Robert’s business ventures. His lesson was learned when he was essentially sold short in his sale of “America’s Biggest,” which could have caused the company to fail – but here Friendable stands today, offering the Fan Pass artist streaming platform to help budding musicians and the fans that follow them have a universal stage to interact and showcase talent. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

Date: January 27-28, 2022 Venue: Online Livestream Dynamic Global Events (“DGE”) welcomes you to the inaugural Telemedicine Compliance Congress, an online livestream event scheduled for January 27-28, 2022. Designed for health care providers and professionals working in telemedicine companies expanding quality patient care, the extraordinary two-day event promises to provide lessons most recently learned in the field of telemedicine, especially in light of recent initiatives by regulatory and oversight bodies as well as the current complex and rapidly evolving issues facing health care providers and telemedicine companies. The COVID-19 pandemic dramatically enhanced the adoption of telemedicine, which has subsequently changed how patients receive care. It also saw many exceptions and waivers granted for telehealth regulations at the federal and state levels. With the ever-increasing proportion of the vaccinated populace, it remains unclear whether the regulatory changes that came into effect because of the pandemic will remain. Still, there is so much to explore regarding the challenges and opportunities resulting from the use of telemedicine. It is against this backdrop that the Telemedicine Compliance Congress will be held. The event will feature these and more talking points on its agenda and explore the associative challenges and opportunities. The first day will kick off with a keynote presentation entitled ‘Identify success factors for managing risk in telehealth services.’ Delivered by Kate Connelly, the Corporate Director, Enterprise Risk Management at Mass General Brigham, this presentation is designed to help stakeholders to unravel the complexities and potential risks in telehealth programs, identify their roles in risk identification and management, and acquire knowledge on how to create awareness for ethics and compliance across telehealth programs. Connelly’s presentation will kickstart a series of panel discussions, case study analyses, and presentations, spread across the two days, involving more than 15 speakers drawn from the Cincinnati Children’s Hospital Medical Center, Johns Hopkins Medicine, Northwell Health, Geisinger Health System, UPMC, CTeL, among other organizations. The speakers will cover topics such as navigating regulatory/compliance challenges in telebehavioral health, understanding the landscape for remote patient monitoring, the impact of COVID-19 on telehealth reimbursement, and an update on the state-to-state regulations and licensure and how to navigate the regulatory changes. In addition, they will discuss the barriers and potential solutions for equitable access to telemedicine, among other topics. In addition to providing insights into how to navigate the telemedicine landscape amid emerging changes, the upcoming event is packed with lessons on what stakeholders have learned throughout their telehealth journeys. It also offers an opportunity for attendees to gain strategies on what they need to help them understand their respective roles in compliance risk management and operating with integrity. The Telemedicine Compliance Congress is designed for professionals from the medical provision and telemedicine companies with responsibilities in telehealth and telemedicine, remote patient monitoring, telepsychiatry, physician services, counsel, behavioral health, privacy, compliance and regulatory affairs, risk management, surgical systems, virtual, digital, and technology. For more information, please visit https://ibn.fm/apHyC